[1] M. F. Beal, “Mitochondrial dysfunction in neurodegenerative diseases,” Biochimica et Biophysica Acta, vol. 1366, no. 1-2, pp. 211–223, 1998.
[2] M. F. Beal, “Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S189–S194, 2009.
[3] D. C. Wallace and W. Fan, “The pathophysiology of mitochondrial disease as modeled in the mouse,” Genes and Development, vol. 23, no. 15, pp. 1714–1736, 2009.
[4] D. C. Wallace, “Mitochondrial diseases in man and mouse,” Science, vol. 283, no. 5407, pp. 1482–1488, 1999.
[5] E. A. Schon, S. DiMauro, M. Hirano, and R. W. Gilkerson, “Therapeutic prospects for mitochondrial disease,” Trends in Molecular Medicine, vol. 16, no. 6, pp. 268–276, 2010.
[6] S. DiMauro and E. A. Schon, “Mitochondrial disorders in the nervous system,” Annual Review of Neuroscience, vol. 31, pp. 91–123, 2008.
[7] S. DiMauro and E. A. Schon, “Mitochondrial respiratory- chain diseases,” New England Journal of Medicine, vol. 348, no. 26, pp. 2656–2668, 2003.
[8] D. Brealey, S. Karyampudi, T. S. Jacques et al., “Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure,” American Journal of Physiology, vol. 286, no. 3, pp. R491–R497, 2004.
[9] G. T. Rezin, G. Amboni, A. I. Zugno, J. Quevedo, and E. L. Streck, “Mitochondrial dysfunction and psychiatric disorders,” Neurochemical Research, vol. 34, no. 6, pp. 1021– 1029, 2009.
[10] B. Rollins, M. V. Martin, P. A. Sequeira et al., “Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder,” PLoS One, vol. 4, no. 3, Article ID e4913, 2009.
[11] J. Miquel, A. C. Economos, J. Fleming, and J. E. Johnson, “Mitochondrial role in cell aging,” Experimental Gerontology, vol. 15, no. 6, pp. 575–591, 1980.
[12] S. Raha and B. H. Robinson, “Mitochondria, oxygen free radicals, disease and ageing,” Trends in Biochemical Sciences, vol. 25, no. 10, pp. 502–508, 2000.
[13] M. L. Genova, M. M. Pich, A. Bernacchia et al., “The mitochondrial production of reactive oxygen species in relation to aging and pathology,” Annals of the New York Academy of Sciences, vol. 1011, pp. 86–100, 2004.
[14] M. Martin, M. Macias, G. Escames, J. Leon, and D. Acuna- Castroviejo, “Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress,” FASEB Journal, vol. 14, no. 12, pp. 1677–1679, 2000.
[15] M. Martın, M. Macıas, G. Escames et al., “Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo,” Journal of Pineal Research, vol. 28, no. 4, pp. 242– 248, 2000.
[16] M. Martın, M. Macıas, J. Le on,  ́ G. Escames, H. Khaldy, and D. Acu na-Castroviejo, “Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 4, pp. 348–357, 2002.
[17] J. Leon, D. Acu na-Castroviejo, R. M. Sainz, J. C. Mayo, D. X. Tan, and R. J. Reiter, “Melatonin and mitochondrial function,” Life Sciences, vol. 75, no. 7, pp. 765–790, 2004.
[18] A. L opez,  ́ J. A. Garcıa, G. Escames et al., “Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production,” Journal of Pineal Research, vol. 46, no. 2, pp. 188–198, 2009.
[19] D. A. Castroviejo, L. C. L opez,  ́ G. Escames, A. L opez,  ́ J. A. Garcıa, and R. J. Reiter, “Melatonin-mitochondria interplay in health and disease,” Current Topics in Medicinal Chemistry, vol. 11, no. 2, pp. 221–240, 2011.
[20] S. Anderson, A. T. Bankier, and B. G. Barrell, “Sequence and organization of the human mitochondrial genome,” Nature, vol. 290, no. 5806, pp. 457–465, 1981.
[21] O. G. Berg and C. G. Kurland, “Why mitochondrial genes are most often found in nuclei,” Molecular Biology and Evolution, vol. 17, no. 6, pp. 951–961, 2000.
[22] G. Schatz, “Mitochondria: beyond oxidative phosphorylation,” Biochimica et Biophysica Acta, vol. 1271, no. 1, pp. 123– 126, 1995.
[23] G. Lenaz and M. L. Genova, “Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject,” Antioxidants and Redox Signaling, vol. 12, no. 8, pp. 961–1008, 2010.
[24] I. Lee, E. Bender, S. Arnold, and B. Kadenbach, “New control of mitochondrial membrane potential and ROS formation— a hypothesis,” Biological Chemistry, vol. 382, no. 12, pp. 1629–1636, 2001.
[25] M. L. Genova, B. Ventura, G. Giuliano et al., “The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2,” FEBS Letters, vol. 505, no. 3, pp. 364–368, 2001.
[26] P. Ghafourifar and C. Richter, “Nitric oxide synthase activity in mitochondria,” FEBS Letters, vol. 418, no. 3, pp. 291–296, 1997.
[27] P. Mander and G. C. Brown, “Nitric oxide, hypoxia and brain inflammation,” Biochemical Society Transactions, vol. 32, no. 6, pp. 1068–1069, 2004.
[28] E. Esposito and S. Cuzzocrea, “Antiinflammatory activity of melatonin in central nervous system,” Current Neuropharmacology, vol. 8, no. 3, pp. 228–242, 2010.
[29] J. Murray, S. W. Taylor, B. Zhang, S. S. Ghosh, and R. A. Capaldi, “Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry,” Journal of Biological Chemistry, vol. 278, no. 39, pp. 37223–37230, 2003.
[30] H. Rubbo, R. Radi, M. Trujillo et al., “Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives,” Journal of Biological Chemistry, vol. 269, no. 42, pp. 26066–26075, 1994.
[31] E. R. Stadtman and R. L. Levine, “Free radical-mediated oxidation of free amino acids and amino acid residues in proteins,” Amino Acids, vol. 25, no. 3-4, pp. 207–218, 2003.
[32] R. L. Levine and E. R. Stadtman, “Oxidative modification of proteins during aging,” Experimental Gerontology, vol. 36, no. 9, pp. 1495–1502, 2001.
[33] J. S. Kim, L. He, and J. J. Lemasters, “Mitochondrial permeability transition: a common pathway to necrosis and apop- tosis,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, pp. 463–470, 2003.
[34] G. Szalai, R. Krishnamurthy, and G. Hajn oczky,  ́ “Apoptosis driven by IP-linked mitochondrial calcium signals,” EMBO Journal, vol. 18, no. 22, pp. 6349–6361, 1999.
[35] J. J. Lemasters, T. P. Theruvath, Z. Zhong, and A. L. Niemi- nen, “Mitochondrial calcium and the permeability transition in cell death,” Biochimica et Biophysica Acta, vol. 1787, no. 11, pp. 1395–1401, 2009.
[36] D. G. Nicholls and S. L. Budd, “Mitochondria and neuronal survival,” Physiological Reviews, vol. 80, no. 1, pp. 315–360, 2000.
[37] W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002.
[38] S. I. Liochev and I. Fridovich, “Mechanism of the peroxidase activity of Cu, Zn superoxide dismutase,” Free Radical Biology and Medicine, vol. 48, no. 12, pp. 1565–1569, 2010.
[39] B. Chance, H. Sies, and A. Boveris, “Hydroperoxide metabolism in mammalian organs,” Physiological Reviews, vol. 59, no. 3, pp. 527–605, 1979.
[40] Y. Urata, S. Honma, S. Goto et al., “Melatonin induces γ- glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells,” Free Radical Biology and Medicine, vol. 27, no. 7-8, pp. 838–847, 1999.
[41] I. Antolın, C. Rodriguez, R. M. Sáinz et al., “Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes,” FASEB Journal, vol. 10, no. 8, pp. 882– 890, 1996.
[42] M. I. Pablos, R. J. Reiter, G. G. Ortiz et al., “Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light,” Neurochemistry International, vol. 32, no. 1, pp. 69–75, 1998.
[43] R. J. Reiter, D. X. Tan, C. Osuna, and E. Gitto, “Actions of melatonin in the reduction of oxidative stress: a review,” Journal of Biomedical Science, vol. 7, no. 6, pp. 444–458, 2000.
[44] C. Rodriguez, J. C. Mayo, R. M. Sainz et al., “Regulation of antioxidant enzymes: a significant role for melatonin,” Journal of Pineal Research, vol. 36, no. 1, pp. 1–9, 2004.
[45] V. Jiménez-Ortega, P. Cano, D. P. Cardinali, and A. I. Esquifino, “24-hour variation in gene expression of redox pathway enzymes in rat hypothalamus: effect of melatonin treatment,” Redox Report, vol. 14, no. 3, pp. 132–138, 2009.
[46] M. Hara, M. Yoshida, H. Nishijima et al., “Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats,” Journal of Pineal Research, vol. 30, no. 3, pp. 129–138, 2001.
[47] G. Escames, A. L opez,  ́ J. A. Garcıa et al., “The role of mitochondria in brain aging and the effects of melatonin,” Current Neuropharmacology, vol. 8, no. 3, pp. 182–193, 2010.
[48] A. B. Lerner, J. D. Case, Y. Takahashi, T. H. Lee, and W. Mori, “Isolation of melatonin, the pineal gland factor that lightens melanocytes,” Journal of the American Chemical Society, vol. 80, no. 10, p. 2587, 1958.
[49] A. Carrillo-Vico, J. R. Calvo, P. Abreu et al., “Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance,” The FASEB Journal, vol. 18, no. 3, pp. 537–539, 2004.
[50] A. Slominski, T. W. Fischer, M. A. Zmijewski et al., “On the role of melatonin in skin physiology and pathology,” Endocrine, vol. 27, no. 2, pp. 137–147, 2005.
[51] G. A. Bubenik, “Gastrointestinal melatonin: localization, function, and clinical relevance,” Digestive Diseases and Sciences, vol. 47, no. 10, pp. 2336–2348, 2002.
[52] S. Jimenez-Jorge, A. J. Jimenez-Caliani, J. M. Guerrero et al., “Melatonin synthesis and melatonin-membrane receptor (MT1) expression during rat thymus development: role of the pineal gland,” Journal of Pineal Research, vol. 39, no. 1, pp. 77–83, 2005.